Original Article

Journal of Investigative Dermatology (1993) 101, 135S–137S; doi:10.1111/1523-1747.ep12363200

Prostaglandins Protect Against Murine Hair Injury Produced by Ionizing Radiation or Doxorubicin

Frederick D Malkinson1, Ling Geng1,2 and Wayne R Hanson2

  1. 1Department of Dermatology, Rush-Presbyterian-St. Lukes Medical Center, Chicago, U.S.A.
  2. 2Loyola-Hines Department of Radiotherapy, Hines VA Medical Center, Hines, Illinois, U.S.A.
Top

Abstract

Several years ago we showed that prostaglandins (PGs) are potent radioprotective agents. To investigate further the potential use of these compounds we employed quantitative measures of murine hair loss and regrowth to assess the effects of PG administration before multi-dose fractionated radiation exposures. We compared these results with findings utilizing the thiol compounds WR-2721 or WR-1065, the "gold standard" laboratory radioprotectors. Three weeks after systemic administration of 16–16 dm PGE2 (Upjohn Company) or WR-2721, given 1 h before each dose of 2–4.5 Gy per fraction for 10–15 fractions, regrowing hair counts increased up to 100% compared to irradiated-only skin sites. The thiol compound effects were slightly superior to the PG effects in these studies. Local applications of 16–16 dm PGE2 or WR-1065 given 15 min before each radiation fraction also enhanced post-radiation hair regrowth, although systemic administration of either agent was more effective than the topical route. We also evaluated possible protective effects of PGs given before doxorubicin, measuring murine hair loss 1 week after parenteral injections of the drug. Five daily doses of doxorubicin, 0.1 mg/25 g animal, reduced the number of hairs in a 4.42 mm2 area of skin from 241 plusminus 5 (controls) to 144 plusminus 3. Misoprostol (G.D. Searle & Co.), 25 mug/mouse, applied locally 2 h before each dose of doxorubicin, resulted in 213 plusminus 8 residual hairs. We conclude that clinical use of these compounds may provide significant protection of hair follicles and possibly other normal tissues (skin; oral, rectal, and bladder mucosa) lying within a radiation field or in patients treated with chemotherapeutic agents. Further assessment of possible tumor protection effects are needed, however.

Top

References

  1. Robert, A: An intestinal disease produced experimentally by a prostaglandin deficiency. Gastroenterol 69: 1045–1047, 1975
  2. Robert, A, Nezamis, JE, Lancaster, C, Hanchar, AJ: Cytoprotection by prostaglandins in rats. Gastroenterol 77: 433–443, 1979
  3. Manabe, T, Steer, ML: Protective effects of PGE2 on diet-induced acute pancreatitis in mice. Gastroenterol 78: 777–781, 1980
  4. Stachura, J, Tarnawski, A, Szczudrawa, J: Cytoprotective effect of 16,16 dimethyl prostaglandin E2 (dm PGE2) and some drugs on acute galactosamine induced liver damage in rat. Folia Histochem Cytochem 18: 311–317, 1980
  5. Hanson, WR, Ainsworth, EJ: Dimethyl prostaglandin E2 induces radioprotection in murine intestinal and hematopoietic stem cells. Radiat Res 103: 196–203, 1985 | PubMed |
  6. Hanson, WR, Pelka, AE, Nelson, AK, Malkinson, FD: Subcutaneous or topical administration of 16,16 dimethyl prostaglandin E2 protects from radiation-induced alopecia in mice. Int J Radiat Oncol Biol Phys 23: 333–337, 1992
  7. Geng, L, Hanson, WR, Malkinson, FD: Topical or systemic 16,16 dm prostaglandin E2 or WR-2721 (WR-1065) protects mice from alopecia after fractionated irradiation. Int J Radiat Biol 61: 533–537, 1992
  8. Malkinson, FD, Griem, ML, Marianovic, R: Effects of hydroxyurca and radiation on hair matrix cells. Cell Tiss Kinet 6: 395–405, 1973
  9. Malkinson, FD, Hanson, WR: Radiobiology of the skin. In: LA Goldsmith (ed.). Physiology, Biochemistry, and Molecular Biology of the Skin 2nd ed. Oxford University Press, New York, pp 976–1013, 1991
  10. Malkinson, FD, Griem, ML, Phillips, DM, Morse, PH: Cysteamine protection of x-ray induced dysplasia in mouse hair. Radiat Res 19: 324–330, 1963
  11. Echols, FS, Yuhas, JM: Chemoprotection against fractionated radiation exposures with WR-2721; skin injury. Radiat Res 66: 499–504, 1976
  12. Glover, D, Fox, KR, Weiler, C, Kligerman, MM, Tunisi, A, Glick, JH: Clinical trials of WR-2721 prior to alkylating agent chemotherapy and radiotherapy. Pharmacol Ther 39: 3–7, 1988 | PubMed |
  13. Hanson, WR: An overview of eicosanoid-induced radiation protection. In: Hohn KV, Marnett LL, Nigam S, Waiden T (eds.). Eicosanoids and Other Bioactive Lipids in Cancer and Radiation Injury Norwall, Massachusetts, pp 111–115, 1991
  14. Hanson, WR: Radiation protection by exogenous arachidonic acid and several metabolites. In: Walden TL, Hughes HM (eds.). Prostaglandin and Lipid Metabolism in Radiation Injury New York, Plenum Press, pp 233–244, 1987
  15. Walden, TL Jr, Holahan, EV Jr, Catravas, GN: Development of a model system to study leukotriene-induced modification of radiation sensitivity in mammalian cells. Prog Lipid Res 25: 587–590, 1986
  16. Nicolau, G, Dahlin, DC, Kohlbrenncr, M: Skin metabolism and transdermal absorption of viprostol, a synthetic PGE2 analogue, in the rat: effect of vehicle. Skin Pharmacol 2: 22–29, 1989

Extra navigation

.
ADVERTISEMENT